Avalon's cancer drug heads to midstage testing - Washington Business Journal:

axilecyqih.wordpress.com
Phase II is the midpoint of human testing for a drug underclinical development. Generally speaking, the firsty phase tests for safety, the second phase tests for safety and while the third and pivotal phase tests for efficacy in a larger patient population. Germantown-based Avalon said the midstage studty of its experimental drug AVN944 is open for enrollment as patiente are being evaluated to beginbstudy treatment. The first active site is Yale University's cancer Avalon (NASDAQ: AVRX) said it expects to enroll patients at about 15 sites for the PhaseII trial, whichu will be conducted in two parts.
The firstg part of the trial will enrollp about 15 to20 patients, while the second part of the triapl will include approximately 110 to 120 "We believe AVN944 has the potential to provider patient benefit in several cancer Avalon President and CEO Kenneth Carter said in a Avalon filed an investigational new drug application with the U.S. Food and Drug Administrationn in August 2005 and began Phaswe I clinical trials in the United States in Januaruy 2006 for the treatment ofhematological cancers.